Acquisition of an AKTAxpress MAb System

收购 AKTAxpress MAb 系统

• 批准号: 7389019
• 负责人: ALBERT B REYNOLDS
• 金额: $ 11.6万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7389019
• 关键词: Academic Medical Centers; Antibodies; Appendix; Area; Budgets; Cancer Center; Chromatography; Community Healthcare; Core Facility; Country; Equipment; Explosion; Funding; Health; Health Services Research; Healthcare; Housing; Human Resources; Lead; Malignant Neoplasms; Mass Spectrum Analysis; Mission; Monoclonal Antibodies; Proteomics; Quality Control; Range; Reagent; Reproduction spores; Request for Applications; Research; Research Personnel; Resource Sharing; Role; Savings; Services; Standards of Weights and Measures; System; Therapeutic; Time; Xenopus; Zebrafish; anticancer research; clinical application; gastrointestinal; instrument; malignant breast neoplasm; programs; success; therapeutic target; tool

DESCRIPTION (provided by applicant): This application requests funds to purchase a dedicated high throughput chromatography system (GE Healthcare AKTAxpress MAb) to automate and standardize the purification of monoclonal antibodies (mAbs). The instrument will be housed and operated by the Vanderbilt Monoclonal Antibody Core (VMAC) in support of several major Vanderbilt users, including the Vanderbilt-Ingram Cancer Center (VICC), two Special Programs of Research Excellence (Gastrointestinal and Breast Cancer SPOREs), the Zebrafish and Xenopus Consortia, and a wide spectrum of research programs within the Vanderbilt University Medical Center (VUMC) that use the VMAC to generate and purify mAbs for NIH-sponsored research. The vast majority of these users are involved in cancer- or other health-related research efforts. Over the past ten years, Vanderbilt has built one of the finest Core Facility Networks in the country. Enormous success in discovery areas such as proteomics, mass spectrometry, and targeted therapeutics (see Research Programs and Shared Resources in appendix) has lead to an explosion in demand for VMAC services. In turn, a critical bottleneck has developed with respect to our ability to provide purified antibodies for our major users. Substantial improvement in both throughput and quality control are necessary to meet the increased overall demand and the higher standards associated with therapeutic applications. The requested equipment will meet these needs and free up time of key personnel for efforts that cannot be readily automated. Importantly, the savings in a single year to NIH-funded researchers (over $500,000) could significantly exceed the entire yearly budget for the VMAC facility. Monoclonal antibodies are critically important tools in a broad range of research and clinical applications used to study and treat cancer. A key role of the VMAC is to accelerate progress in multiple areas of health and cancer research by making these crucial reagents inexpensive, easy to make, and readily available to the Vanderbilt research and healthcare community. The instrument described in this application is central to this mission.

描述（由申请人提供）：本申请要求资金购买专用的高通量层析系统（GE Healthcare AKTAxpress MAb），以自动化和标准化单克隆抗体（mAb）的纯化。该仪器将由范德比尔特单克隆抗体核心 (VMAC) 安置和运营，以支持范德比尔特的几个主要用户，包括范德比尔特-英格拉姆癌症中心 (VICC)、两个卓越研究特别计划（胃肠癌和乳腺癌孢子）、斑马鱼和爪蟾联盟以及范德比尔特大学医学中心 (VUMC) 内使用的广泛研究计划 VMAC 为 NIH 资助的研究生成和纯化 mAb。这些用户中的绝大多数都参与了癌症或其他与健康相关的研究工作。在过去的十年中，范德比尔特建立了全国最好的核心设施网络之一。蛋白质组学、质谱分析和靶向治疗等发现领域取得的巨大成功（参见附录中的研究计划和共享资源）导致对 VMAC 服务的需求激增。反过来，我们为主要用户提供纯化抗体的能力出现了一个关键瓶颈。为了满足不断增长的总体需求和与治疗应用相关的更高标准，必须大幅提高通量和质量控制。所需的设备将满足这些需求，并腾出关键人员的时间来进行无法轻易自动化的工作。重要的是，NIH 资助的研究人员一年内节省的费用（超过 500,000 美元）可能大大超过 VMAC 设施的整个年度预算。单克隆抗体是用于研究和治疗癌症的广泛研究和临床应用中至关重要的工具。 VMAC 的一个关键作用是通过使这些关键试剂价格低廉、易于制造且易于范德比尔特研究和医疗保健社区使用，来加速健康和癌症研究多个领域的进展。本申请中描述的仪器是该任务的核心。